Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation status is required to optimally treat patients wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curr Oncol
Hauptverfasser: Cheema, P.K., Gomes, M., Banerji, S., Joubert, P., Leighl, N.B., Melosky, B., Sheffield, B.S., Stockley, T., Ionescu, D.N.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Multimed Inc. 2020
Schlagworte:
Practice Guideline
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755440/
https://ncbi.nlm.nih.gov/pubmed/33380864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.7297
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge